MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Sen, Anagha ^a   Ren, Shumei ^a   Lerchenmüller, Carolin ^b   Sun, Jianxin ^a   Weiss, Norbert ^c   Most, Patrick ^a,b   Peppel, Karsten ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 138; NITRIC OXIDE SYNTHASE; PROTEIN S 100; PROTEIN S 100A1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMORAL ARTERY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; VASCULAR SMOOTH MUSCLE;

3' UNTRANSLATED REGIONS; ANIMALS; CELL HYPOXIA; CELL LINE; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; ISCHEMIA; MALE; MICE; MICRORNAS; S100 PROTEINS;

EID: 84892943787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078684     Document Type: Article

References (28)

1. Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33: 829-837.
2. Brevetti G, Schiano V, Chiariello M (2008) Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis 197: 1-11.
3. Most P, Lerchenmüller C, Rengo G, Mahlmann A, Ritterhoff J, et al. (2013) S100A1 Deficiency Impairs Postischemic Angiogenesis Via Compromised Proangiogenic Endothelial Cell Function and Nitric Oxide Synthase Regulation. Circ Res 112: 66-78.
4. Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z (2003) The microRNA world: small is mighty. Trends Biochem Sci 28: 534-540.
5. Murray JK, Balan C, Allgeier AM, Kasparian A, Viswanadhan V, et al. (2010) Dipeptidyl-quinolone derivatives inhibit hypoxia inducible factor-1alpha prolyl hydroxylases-1, -2, and -3 with altered selectivity. J Comb Chem 12: 676-686.
6. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
7. Pleger ST, Harris DM, Shan C, Vinge LE, Chuprun JK, et al. (2008) Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 102: 786-794.
8. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153.
9. Bar M, Wyman SK, Fritz BR, Qi J, Garg KS, et al. (2008) MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells 26: 2496-2505.
10. Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, et al. (2010) Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS One 5: e9685.
11. Brinks H, Rohde D, Voelkers M, Qiu G, Pleger ST, et al. (2011) S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 58: 966-973.
12. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R (2001) Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-75.
13. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131-3139.
14. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, et al. (2001) S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A 98: 13889-13894.
15. Prosser BL, Hernandez-Ochoa EO, Schneider MF (2011) S100A1 and calmodulin regulation of ryanodine receptor in striated muscle. Cell Calcium 50: 323-331.
16. Benfenati F, Ferrari R, Onofri F, Arcuri C, Giambanco I, et al. (2004) S100A1 codistributes with synapsin I in discrete brain areas and inhibits the F-actinbundling activity of synapsin I. J Neurochem 89: 1260-1270.
17. Song T, Zhang X, Wang C, Wu Y, Cai W, et al. (2011) MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev 12: 1307-1311.
18. Yeh YM, Chuang CM, Chao KC, Wang LH (2013) MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer.
19. Obernosterer G, Leuschner PJ, Alenius M, Martinez J (2006) Post-transcriptional regulation of microRNA expression. RNA 12: 1161-1167.
20. Li S, Ran Y, Zhang D, Chen J, Zhu D (2013) MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J 452: 281-291.
21. Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG (2013) MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells. Anticancer Agents Med Chem: in press.
22. Liu X, Lv XB, Wang XP, Sang Y, Xu S, et al. (2012) MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle 11: 2495-2506.
23. Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, et al. (2008) Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99: 280-286.
24. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT (2012) MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33: 1113-1120.
25. Zhang H, Zhao M, Lv Z, Zhang X, Qin X, et al. (2013) MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer. Cell Physiol Biochem 31: 56-65.
26. Lau JF, Weinberg MD, Olin JW (2011) Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. Nat Rev Cardiol 8: 405-418.
27. Weinberg MD, Lau JF, Rosenfield K, Olin JW (2011) Peripheral artery disease. Part 2: medical and endovascular treatment. Nat Rev Cardiol 8: 429-441.
28. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, et al. (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685-1694.